Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset

Thumbnail image

Download files

DOI

https://doi.org/10.1016/j.xcrm.2021.100290

Language of the publication
English
Date
2021-06-15
Type
Article
Author(s)
  • Anand, Sai Priya
  • Prévost, Jérémie
  • Nayrac, Manon
  • Beaudoin-Bussières, Guillaume
  • Benlarbi, Mehdi
  • Gasser, Romain
  • Brassard, Nathalie
  • Laumaea, Annemarie
  • Gong, Shang Yu
  • Bourassa, Catherine
  • Brunet-Ratnasingham, Elsa
  • Medjahed, Halima
  • Gendron-Lepage, Gabrielle
  • Goyette, Guillaume
  • Gokool, Laurie
  • Morrisseau, Chantal
  • Bégin, Philippe
  • Martel-Laferrière, Valérie
  • Tremblay, Cécile
  • Richard, Jonathan
  • Bazin, Renée
  • Duerr, Ralf
  • Kaufmann, Daniel E.
  • Finzi, Andrés
Publisher
Cell Press

Abstract

With the recent approval of highly effective coronavirus disease 2019 (COVID-19) vaccines, functional and lasting immunity to severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) is currently under investigation as antibody levels in plasma were shown to decline during convalescence. Since the absence of antibodies does not equate to absence of immune memory, we evaluate the presence of SARS-CoV-2-specific memory B cells in convalescent individuals. Here, we report a longitudinal assessment of humoral immune responses on 32 donors up to 8 months post-symptom onset. Our observations indicate that anti-Spike and anti-receptor binding domain (RBD) immunoglobulin M (IgM) in plasma decay rapidly, whereas the reduction of IgG is less prominent. Neutralizing activity also declines rapidly when compared to Fc-effector functions. Concomitantly, the frequencies of RBD-specific IgM+ B cells wane significantly when compared to RBD-specific IgG+ B cells, which remain stable. Our results add to the current understanding of immune memory following SARS-CoV-2 infection, which is critical for secondary infection prevention and vaccine efficacy.

Subject

  • Health

Keywords

  • ADCC,
  • COVID-19,
  • RBD,
  • SARS-CoV-2,
  • Spike glycoproteins,
  • antibodies,
  • coronavirus,
  • humoral responses,
  • memory B cells,
  • neutralization.

Rights

Peer review

Yes

Identifiers

PubMed ID
33969322
ISSN
2666-3791

Article

Journal title
Cell Reports Medicine
Journal volume
2
Journal issue
6

Citation(s)

Anand SP, Prévost J, Nayrac M, Beaudoin-Bussières G, Benlarbi M, Gasser R, Brassard N, Laumaea A, Gong SY, Bourassa C, Brunet-Ratnasingham E, Medjahed H, Gendron-Lepage G, Goyette G, Gokool L, Morrisseau C, Bégin P, Martel-Laferrière V, Tremblay C, Richard J, Bazin R, Duerr R, Kaufmann DE, Finzi A. Longitudinal analysis of humoral immunity against SARS-CoV-2 Spike in convalescent individuals up to 8 months post-symptom onset. Cell Rep Med. 2021 Jun 15;2(6):100290. doi: 10.1016/j.xcrm.2021.100290. Epub 2021 May 5.

Download(s)

URI

Collection(s)

Public health surveillance

Full item page

Full item page

Page details

Date modified: